Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jac/dkw200PMID 27272723
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.

  2015cited by this paper
• Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii

  2014cited by this paper
• Evaluation of Meropenem Regimens Suppressing Emergence of Resistance in Acinetobacter baumannii with Human Simulated Exposure in an In Vitro Intravenous-Infusion Hollow-Fiber Infection Model

  2014cited by this paper
• Exposure to Ceftobiprole Is Associated with Microbiological Eradication and Clinical Cure in Patients with Nosocomial Pneumonia

  2014cited by this paper
• Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.

  2014cited by this paper
• Imipenem, Meropenem, or Doripenem To Treat Patients with Pseudomonas aeruginosa Ventilator-Associated Pneumonia

  2013cited by this paper
• Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia

  2013cited by this paper
• Pharmacodynamics of the Antibacterial Effect of and Emergence of Resistance to Doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an In Vitro Pharmacokinetic Model

  2012cited by this paper
• Optimization of meropenem dosage in the critically ill population based on renal function

  2011cited by this paper
• Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia

  2011cited by this paper
• The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression

  2010cited by this paper
• Mutant Prevention Concentrations of Four Carbapenems against Gram-Negative Rods

  2010cited by this paper
• Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.

  2009cited by this paper
• Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa

  2009cited by this paper
• Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

  2008cited by this paper
• Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.

  2007cited by this paper
• Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of Pseudomonas aeruginosa

  2005cited by this paper
• Prevention of resistance: a goal for dose selection for antimicrobial agents.

  2003cited by this paper
• Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

  1998cited by this paper

• Duration Matters: Tailoring Antibiotic Therapy for Ventilator-Associated Pneumonia

  2026cites this paper
• Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing

  2024cites this paper
• Early Target Attainment With Continuous Infusion Meropenem and Piperacillin/Tazobactam and Utilization of Therapeutic Drug Monitoring in Critically Ill Patients: A Retrospective Cohort Study From 2017 to 2020.

  2023cites this paper
• Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review

  2023cites this paper
• The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting

  2023cites this paper
• Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective

  2022cites this paper
• Empirical Antibiotic Therapy for Gram-Negative Bacilli Ventilator-Associated Pneumonia: Observational Study and Pharmacodynamic Assessment

  2022cites this paper
• Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man

  2022cites this paper
• A Systematic Review of the Effect of Therapeutic Drug Monitoring on Patient Health Outcomes during Treatment with Carbapenems

  2022cites this paper
• Parametric and Nonparametric Population Pharmacokinetic Models to Assess Probability of Target Attainment of Imipenem Concentrations in Critically Ill Patients

  2021cites this paper
• Optimized Dosing Regimens of Meropenem in Septic Children Receiving Extracorporeal Life Support

  2021cites this paper
• A guide to therapeutic drug monitoring of β‐lactam antibiotics

  2021cites this paper
• Association of Increased Circulating Acetic Acid With Poor Survival in Pseudomonas aeruginosa Ventilator-Associated Pneumonia Patients

  2021cites this paper
• Pseudomonas aeruginosa necrotizing bronchopneumonia

  2021cites this paper
• Applying Antimicrobial Pharmacokinetic Principles for Complex Patients: Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation and Renal Replacement Therapy

  2021cites this paper
• Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia

  2021cites this paper
• Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects

  2021cites this paper
• A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients.

  2021cites this paper
• Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range

  2021cites this paper
• In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model.

  2020cites this paper
• Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007)

  2019cites this paper
• Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model

  2018cites this paper
• Individualising Therapy to Minimize Bacterial Multidrug Resistance

  2018cites this paper
• Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients

  2017cites this paper
• Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria

  2017cites this paper
• Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients

  2017cites this paper
• Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study

  2017cites this paper
• Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria

  2016cites this paper